Overview
PFF Summit Highlights: News You Can Use
Updates in the Diagnosis and Management of ILD
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Across three brief videos, expert faculty Dr. Joseph Lasky discusses highlights and data from the PFF Summit 2021, which took place virtually. Dr. Lasky provides insights into updated diagnostic guidance, emerging therapies, and patient perspectives across the spectrum of interstitial lung diseases (ILD). Don’t miss this opportunity to hear the latest research in ILD!
This activity is intended for pulmonologists, radiologists, respiratory therapists, and other healthcare clinicians interested in managing patients with ILDs.
A differential diagnosis of ILD can be challenging and patients often experience delays, but an accurate diagnosis is necessary to guide therapy selection. Once diagnosed, patients require a comprehensive care plan that includes pharmacotherapy and supportive care. A number of additional agents are also under investigation across the ILDs to expand options for patients. As such, the multidisciplinary team requires up-to-date information to ensure that patients receive the latest care.
Upon completion of this activity, participants will be able to:
• Describe the different types of ILDs and distinguishing features that guide a differential diagnosis
• Evaluate results of recently published trials that influence treatment selection for diverse patients with ILD
• Discuss the impact emerging data may have on the management of patients with ILD
• Describe the different types of ILDs and distinguishing features that guide a differential diagnosis
• Evaluate results of recently published trials that influence treatment selection for diverse patients with ILD
• Discuss the impact emerging data may have on the management of patients with ILD
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
The activity was developed in partnership with the Pulmonary Fibrosis Foundation (PFF).
Supported by an educational grant from Genentech, Inc.
Joseph Lasky, MD
Professor of Medicine and Pulmonary and Critical Care Section Chief
Department of Medicine
Tulane University
New Orleans, LA
Chief Medical Officer
Pulmonary Fibrosis Foundation
Chicago, IL
Professor of Medicine and Pulmonary and Critical Care Section Chief
Department of Medicine
Tulane University
New Orleans, LA
Chief Medical Officer
Pulmonary Fibrosis Foundation
Chicago, IL
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.
The following financial relationships have been provided:
Joseph Lasky, MD, (Faculty)
Advisory Board: Boehringer Ingelheim, Galecto, Roche, United Therapeutics, Veracyte
Research Trial: United Therapeutics, Veracyte
Speakers’ Bureau: Boehringer Ingelheim, Veracyte
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Pamrevlumab, recombinant human pentraxin-2, inhaled treprostinil, GB0139 (a galectin-3 inhibitor), PLN-74809 (a TGF-beta inhibitor), and other agents under investigation for ILD.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
